Featured Image
Why is it important?
Last years in CKD 4-5 we were substituting ACEi/ARB by sympatholytic agents in order to maintain compensatory hyperfiltration and provide more prominent BP reduction. Clinical results show enlargement of period to renal replacement therapy (RRT) and trend to decreasing cardiovascular mortality. Thus formula ARAMONEL - AR(B)A(CEI)MO(xonidine)NE(bivolol)L(ercandipine) in CKD1-3b was changed to the following one: MONELED - MO(xonidine)NE(bivolol)LE(rcandipine)D(iuretic) in CKD 4-5.
Perspectives
Our clinical practice shows feasibility using sympatolytic agents instead ACEi/ARB in CKD4-5 stages as a novel concept. In one year the evident background of 3 years follow-up will be presented.
Prof Dmytro D Ivanov
Shupyk National Medical Academy of Postgraduate Education
Read the Original
This page is a summary of: Antihypertensive Treatment and Kidney Function in Routine Practice in Patients with Type 2 Diabetes Mellitus: The Results of the Prospective "The Scythian" Trial in Ukraine, The Open Urology & Nephrology Journal, July 2014, Bentham Science Publishers,
DOI: 10.2174/1874303x01407010071.
You can read the full text:
Contributors
The following have contributed to this page
